These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 24613272)

  • 41. [Sleeping sickness from early diagnosis to post-therapy follow-up].
    Wery M
    Bull Mem Acad R Med Belg; 1986; 141(2):203-12. PubMed ID: 3533186
    [No Abstract]   [Full Text] [Related]  

  • 42. [The use of difluoromethylornithine in congenital trypanosomiasis due to Trypanosoma brucei-gambiense].
    Pepin J; Guern C; Milord F; Ethier L; Bokelo M; Schechter PJ
    Med Trop (Mars); 1989; 49(1):83-5. PubMed ID: 2498607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa.
    Lejon V; Boelaert M; Jannin J; Moore A; Büscher P
    Lancet Infect Dis; 2003 Dec; 3(12):804-8. PubMed ID: 14652206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eflornithine. A new drug in the treatment of sleeping sickness.
    Van Bogaert I; Haemers A
    Pharm Weekbl Sci; 1989 Jun; 11(3):69-75. PubMed ID: 2505225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Human African trypanosomiasis from Trypanosoma brucei gambiense with inoculation chancre in a French expatriate].
    Malvy D; Djossou F; Weill FX; Chapuis P; Longy-Boursier M; Le Bras M
    Med Trop (Mars); 2001; 61(4-5):323-7. PubMed ID: 11803822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Wild fauna as a probable animal reservoir for Trypanosoma brucei gambiense in Cameroon.
    Njiokou F; Laveissière C; Simo G; Nkinin S; Grébaut P; Cuny G; Herder S
    Infect Genet Evol; 2006 Mar; 6(2):147-53. PubMed ID: 16236560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
    Dauchy FA; Bonhivers M; Landrein N; Dacheux D; Courtois P; Lauruol F; Daulouède S; Vincendeau P; Robinson DR
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005125. PubMed ID: 27855164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3 Tesla serial magnetic resonance imaging of human African trypanosomiasis (Trypanosoma brucei gambiense) and review of the literature.
    Boukobza M; Lariven S; Houze S; Laissy JP
    Rev Neurol (Paris); 2021 Nov; 177(9):1176-1182. PubMed ID: 33648780
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Three patients with African sleeping sickness following a visit to Tanzania].
    Mendonça Melo M; Rasica M; van Thiel PP; Richter C; Kager PA; Wismans PJ
    Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2552-6. PubMed ID: 12532670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secreted proteases of Trypanosoma brucei gambiense: possible targets for sleeping sickness control?
    Bossard G; Cuny G; Geiger A
    Biofactors; 2013; 39(4):407-14. PubMed ID: 23553721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
    Schmid C; Kuemmerle A; Blum J; Ghabri S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete D; Mubwa N; Kisala M; Blesson S; Mordt OV
    PLoS Negl Trop Dis; 2012; 6(11):e1920. PubMed ID: 23209861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
    Kuemmerle A; Schmid C; Bernhard S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete DN; Kisala M; Burri C; Blesson S; Valverde Mordt O
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009903. PubMed ID: 34748572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High prevalence of Trypanosoma brucei gambiense group 1 in pigs from the Fontem sleeping sickness focus in Cameroon.
    Simo G; Asonganyi T; Nkinin SW; Njiokou F; Herder S
    Vet Parasitol; 2006 Jun; 139(1-3):57-66. PubMed ID: 16567049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Follow - up prognostic study on two imported patients with human African trypanosomiasis].
    Li YY; Chen XL; Liu Q; Wang XY; Chen MX; Liu Q
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2021 Jun; 33(3):293-296. PubMed ID: 34286532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Late-stage human African trypanosomiasis in a Sudanese refugee.
    Cherian P; Junckerstorff RK; Rosen D; Kumarasinghe P; Morling A; Tuch P; Raven S; Murray RJ; Heath CH
    Med J Aust; 2010 Apr; 192(7):417-9. PubMed ID: 20367593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of Trypanosoma brucei gambiense in the host and alternative sleeping sickness diagnostic approaches.
    Wery M; Mulumba MP
    Ann Soc Belg Med Trop; 1989; 69 Suppl 1():181-7; discussion 212-4. PubMed ID: 2679454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case Report:
    Boodman C; Libman M; Ndao M; Yansouni CP
    Am J Trop Med Hyg; 2019 Jul; 101(1):123-125. PubMed ID: 31074413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of a PCR assay for diagnosing African trypanosomiasis of the CNS: a case report.
    Kirchhoff LV
    Cent Afr J Med; 1998 May; 44(5):134-6. PubMed ID: 9810412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
    Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA
    Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
    Balasegaram M; Harris S; Checchi F; Hamel C; Karunakara U
    Bull World Health Organ; 2006 Oct; 84(10):777-82. PubMed ID: 17128357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.